Lower Protein Intake and Long-term Risk of Obesity and Cardiovascular Disease: A Multi-centred, Randomised, Controlled Trial
| Registry | NCT03456934, acronym BabyGrowth |
|---|---|
| Status | Completed |
| Phase | Not applicable |
| Study type | Interventional; randomized, parallel, masking: quadruple, other |
| Enrollment | 249 (Actual) |
| Sponsor | Société des Produits Nestlé (SPN) (Industry); collaborators: University College, London |
| Conditions | Infant Formula, Growth |
| Interventions | Modified infant formula, Standard infant formula (Other) |
| Dates | start 2017-08-07, primary completion 2021-09-30, completion 2022-10-13, first posted 2018-03-07, last updated 2023-03-17 |
| Locations | 1 site in United Kingdom |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Infant Formula All trials for Growth All trials of Modified infant formula All trials of Standard infant formula
The primary objective of this study is to investigate if consumption of lower protein formula can slow the rate of weight gain of formula-fed infants between 3 and 12 months of age. Secondary objectives include investigation into whether infant nutrition and growth have an impact on later risk of obesity and cardiovascular disease.
Obesity and its cardiovascular consequences are the most important causes of morbidity and mortality worldwide. Breastfed infants have been shown to have less cardiovascular risk factors in adulthood, which can be partially explained by their slower growth compared to formula fed infants. The primary objective of this study is to investigate if consumption of lower protein formula can slow the rate of weight gain of formula-fed infants between 3 and 12 months of age. Secondary objectives include investigation into whether infant nutrition and growth have an impact on later risk of obesity and atherosclerotic cardiovascular disease (CVD), the critical windows for these programming effects, and the mechanisms of action.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Experimental Group | Experimental | Other: Modified infant formula | Modified infant formula given from 3 to 12 months of age, as per standard requirement. |
| Control Group | Active comparator | Other: Standard infant formula | Standard infant formula given from 3 to 12 months of age, as per standard requirement. |
| Breast-fed Reference Group | No intervention | Non-randomized infants who are predominantly breast-fed at time of enrollment. |
Sex: All, ages: 13 Weeks to 15 Weeks, accepts healthy volunteers
Inclusion Criteria: * Healthy term infant * Infant is aged 14 weeks (+/- 1 week) * Infant is exclusively formula feeding or predominantly breast-feeding at age 14 weeks Exclusion Criteria: * Any adverse maternal, fetal or infant medical history that may have effects on growth and/or development * Infant born with congenital disease or malformation affecting growth and/or development * Food allergy to any trial products (e.g. milk, soy)
| Facility | City | Country | Status |
|---|---|---|---|
| UCL Institute of Child Health | London | United Kingdom |